Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceftazidime + sulbactam is a fixed-dose combination injectable antibiotic used primarily for the treatment of severe bacterial infections in hospitalized patients. Ceftazidime is a third-generation cephalosporin that exerts its bactericidal effect by inhibiting bacterial cell wall synthesis, specifically targeting penicillin-binding proteins. Sulbactam is a beta-lactamase inhibitor that protects ceftazidime from enzymatic degradation by beta-lactamase-producing bacteria, thereby broadening its spectrum of activity and enhancing efficacy against resistant organisms. This combination is indicated for complicated intra-abdominal infections, urinary tract infections, hospital-acquired pneumonia, septicemia, bone and joint infections, skin and soft tissue infections, meningitis, post-surgical infections, and serious hospital-acquired or healthcare-associated bacterial diseases[1][4]. It is administered intravenously or intramuscularly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ceftazidime + sulbactam.